Document Detail


Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma.
MedLine Citation:
PMID:  23283519     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The aim of this study was to verify whether pretreatment plasma levels of vascular endothelial growth factor (VEGF) correlate with prognosis and survival of patients with diffuse large B-cell lymphoma (DLBCL). Plasma VEGF levels were assessed at the time of diagnosis in 157 DLBCL patients treated with anthracycline-based chemotherapy. Plasma VEGF levels greater than or equal to the highest quartile (high VEGF levels) were associated with lower probability of a complete remission achievement (odds ratio 0.3; 95 % confidence interval [CI]: 0.1-0.6; p = 0.002) in univariate as well as in multivariate analysis (p = 0.04). The estimated 3-year progression-free survival (PFS) rate of patients with high VEGF levels was 31.7 % (95 % CI 17-51) compared to the 62.5 % 3-year PFS rate (95 % CI 53-71; p = 0.0004) in the patients with lower values. The former group of patients demonstrated an estimated 3-year overall survival (OS) rate of 47.1 % (95 % CI 30-65) in contrast to the 3-year OS rate of 64.3 % (95 % CI 54-73; p = 0.02) in the latter. In multivariate analysis, the high VEGF level retained its independent impact on shorter PFS (p = 0.02). Our results suggest that VEGF plays an important role in the clinical course of DLBCL. VEGF may be a useful marker for selecting the patients for whom new treatment approaches, especially those based on VEGF inhibitors, could be recommended.
Authors:
Ewa Lech-Maranda; Jacques Bienvenu; Florence Broussais-Guillaumot; Anne-Sophie Michallet; Krzysztof Warzocha; Przemysław Biliński; Peter Boyle; Bertrand Coiffier; Gilles Salles
Related Documents :
23302469 - Interactions of mir-323/mir-326/mir-329 and mir-130a/mir-155/mir-210 as prognostic indi...
23606819 - Can neutrophil-lymphocyte ratio and lymph node density be used as prognostic factors in...
23754449 - Human papillomavirus is independent prognostic factor on outcome of oropharyngeal squam...
2294759 - Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia.
10546409 - Lung microcytoma: a multidisciplinary therapeutic approach.
18830669 - Improving the accuracy of tnm staging in esophageal cancer: a pathological review of re...
11992049 - Brain metastases from bladder carcinoma: presentation, treatment and survival.
12781539 - Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins.
12023789 - Pemetrexed combination therapy in the treatment of non-small cell lung cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-3
Journal Detail:
Title:  Archivum immunologiae et therapiae experimentalis     Volume:  -     ISSN:  1661-4917     ISO Abbreviation:  Arch. Immunol. Ther. Exp. (Warsz.)     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0114365     Medline TA:  Arch Immunol Ther Exp (Warsz)     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Equipe d'Accueil "Pathologie des Cellules Lymphoïdes", Université Claude Bernard, Lyon, France, ewamaranda@wp.pl.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differentiation of Stem Cells into Insulin-Producing Cells: Current Status and Challenges.
Next Document:  Culture of major pelvic ganglion neurons from adult rat.